Registry for Esophageal and Gastroesophageal Junction Cancer

Recruiting now

Conditions studied: Gastroesophageal-junction Cancer, Esophageal Cancer

In brief

The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer/GEJ cancer. Researchers will use the information from this database to learn more about the effectiveness of different treatment options.

Key facts

Study ID

NCT06558786

Run by

Memorial Sloan Kettering Cancer Center

People needed

50

Starts

2024-08-12

Expected to finish

2029-08-12

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed stage IV adenocarcinoma of the esophagus or GEJ with OMD at the time of diagnosis, defined as the following:
• Retroperitoneal lymph nodes (e.g., para-aortal, intra-aorto-caval, parapancreatic, or mesenterial lymph node)
• Liver
• Lung
• Extra-abdominal lymph nodes (e.g., supraclavicular or cervical lymph nodes)
• Adrenal gland
• Unilateral or bilateral ovarian metastases (in the absence of gross or microscopic peritoneal disease [positive cytology])
• Bone
• ≤2 sites of disease (excluding the primary tumor and regional lymph nodes)
• ≤3 tumors within each organ system
• ≤5 metastases
• All nonregional lymph nodes (including cervical, supraclavicular, and retroperitoneal nodal disease) are considered 1 discrete lesion
• Satellite lesions in the primary esophageal malignancy, such as skipped esophageal primaries, are not considered metastatic sites
• All sites of disease must be amenable to complete local therapy after systemic therapy, according to the treating physician. Treatment modalities include:
• Surgery
• Definitive chemoradiation
• Stereotactic radiation
• Ablation or similar techniques (e.g., irreversible electroporation)
• Age ≥18 years

You may not qualify if…

• Presence of metastases, at the time of diagnosis, to the following:
• Peritoneum, including positive peritoneal lavage (on the basis of baseline diagnostic laparoscopy to rule out gross disease and positive peritoneal lavage cytology; laparoscopy may be omitted for patients in whom all sites of disease are above the diaphragm)
• Malignant pleural effusion
• Brain metastases or leptomeningeal disease
• Other sites not specifically noted must be reviewed and approved by the PIs
• Any site of disease that is not amenable to definitive local therapy
• Unfit for best systemic therapy
• Metachronous OMD
• Secondary primary cancer, with the exclusion of basal cell carcinoma of the skin
• Pregnant, lactating, or intending to become pregnant
• Unwilling to provide informed consent

Where it is running

• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.